These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 34866586)

  • 21. Mid-term outcomes of bioresorbable vascular scaffolds vs second-generation drug-eluting stents in patients with acute coronary syndromes: A systematic review and meta-analysis.
    Ke J; Zhang H; Huang J; Lv P; Yan J
    Medicine (Baltimore); 2020 Mar; 99(10):e19458. PubMed ID: 32150103
    [TBL] [Abstract][Full Text] [Related]  

  • 22. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stent Thrombosis With Drug-Eluting Stents and Bioresorbable Scaffolds: Evidence From a Network Meta-Analysis of 147 Trials.
    Kang SH; Chae IH; Park JJ; Lee HS; Kang DY; Hwang SS; Youn TJ; Kim HS
    JACC Cardiovasc Interv; 2016 Jun; 9(12):1203-1212. PubMed ID: 27262860
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Current Literature on Bioabsorbable Stents: a Review.
    Omar WA; Kumbhani DJ
    Curr Atheroscler Rep; 2019 Nov; 21(12):54. PubMed ID: 31768641
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Poly (l-lactic acid) bioresorbable scaffolds versus metallic drug-eluting stents for the treatment of coronary artery disease: A meta-analysis of 11 randomized trials.
    Verdoia M; Kedhi E; Suryapranata H; Galasso G; Dudek D; De Luca G
    Catheter Cardiovasc Interv; 2020 Oct; 96(4):813-824. PubMed ID: 31730255
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transradial experience with bioresorbable vascular scaffolds: A case-matched study with metallic drug-eluting stents.
    Maes F; Costerousse O; Cieza T; Henry M; Déry JP; Barbeau G; Delarochellière R; Paradis JM; Larose E; Nguyen CM; Pirlet C; Mongrain R; Bertrand OF
    Cardiovasc Revasc Med; 2018 Sep; 19(6):700-704. PubMed ID: 29398632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-Term Clinical Outcomes After Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-Stent Restenosis: A Multicenter Italian Experience.
    Moscarella E; Ielasi A; Granata F; Coscarelli S; Stabile E; Latib A; Cortese B; Tespili M; Tanaka A; Capozzolo C; Caliendo L; Colombo A; Varricchio A
    Circ Cardiovasc Interv; 2016 Apr; 9(4):e003148. PubMed ID: 27059683
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term outcomes of bioresorbable vascular scaffold in ST-elevation myocardial infarction.
    de Hemptinne Q; Picard F; Ly HQ; Ibrahim R; Asgar AW; de Guise P; Doucet S; Dorval JF; Marquis-Gravel G; Levi M; L-L'allier P; Tanguay JF
    Acta Cardiol; 2018 Jun; 73(3):276-281. PubMed ID: 28954592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison Between Bare-Metal Stents, First-Generation Drug-Eluting Stents, and Bioresorbable Vascular Scaffolds.
    Ng AK; Ng PY; Siu CW; Jim MH
    J Invasive Cardiol; 2021 Jun; 33(6):E467-E473. PubMed ID: 34077386
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bioresorbable vascular stents and drug-eluting stents in treatment of coronary heart disease: a meta-analysis.
    Ni L; Chen H; Luo Z; Yu Y
    J Cardiothorac Surg; 2020 Jan; 15(1):26. PubMed ID: 31992360
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction).
    Brugaletta S; Gori T; Low AF; Tousek P; Pinar E; Gomez-Lara J; Scalone G; Schulz E; Chan MY; Kocka V; Hurtado J; Gomez-Hospital JA; Münzel T; Lee CH; Cequier A; Valdés M; Widimsky P; Serruys PW; Sabaté M
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):189-197. PubMed ID: 25616924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Edge-to-Edge Technique to Minimize Ovelapping of Multiple Bioresorbable Scaffolds Plus Drug Eluting Stents in Revascularization of Long Diffuse Left Anterior Descending Coronary Artery Disease.
    Rigatelli G; Avvocata FD; Ronco F; Giordan M; Roncon L; Caprioglio F; Grassi G; Faggian G; Cardaioli P
    J Interv Cardiol; 2016 Jun; 29(3):275-84. PubMed ID: 27245123
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bioresorbable Vascular Scaffolds Versus Drug-Eluting Stents for Diffuse Long Coronary Narrowings.
    Seo J; Ahn JM; Hong SJ; Kang DY; Hong SJ; Her AY; Kim YH; Ahn CM; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Park SJ; Park DW; Hong MK
    Am J Cardiol; 2020 Jun; 125(11):1624-1630. PubMed ID: 32279841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early experience and favorable clinical outcomes of everolimus-eluting bioresorbable scaffolds for coronary artery disease in Korea.
    Kwon O; Ahn JM; Kang DY; Kang SH; Lee PH; Kang SJ; Lee SW; Kim YH; Lee CW; Park SW; Park DW; Park SJ
    Korean J Intern Med; 2018 Sep; 33(5):922-932. PubMed ID: 29108400
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Everolimus-eluting bioresorbable scaffolds for treatment of coronary artery disease in patients with diabetes mellitus: the midterm follow-up of the prospective ABSORB DM Benelux study.
    Hommels TM; Hermanides RS; Rasoul S; Berta B; IJsselmuiden AJJ; Jessurun GAJ; Benit E; Pereira B; De Luca G; Kedhi E
    Cardiovasc Diabetol; 2019 Mar; 18(1):25. PubMed ID: 30851731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intraindividual Comparison of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Drug-Eluting Metallic Stents.
    Cassese S; Hoppmann P; Kufner S; Byrne RA; Wiebe J; Colleran R; Giacoppo D; Harada Y; Laugwitz KL; Schunkert H; Fusaro M; Kastrati A
    Circ Cardiovasc Interv; 2016 Aug; 9(8):. PubMed ID: 27512088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mid-term clinical outcomes of ABSORB bioresorbable vascular scaffold implantation in a real-world population: A single-center experience.
    Costopoulos C; Crowson MC; Brown AJ; Braganza DM; Bennett MR; Hoole SP; West NE
    Cardiovasc Revasc Med; 2015 Dec; 16(8):461-4. PubMed ID: 26440767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Role of Vascular Imaging in Guiding Routine Percutaneous Coronary Interventions: A Meta-Analysis of Bare Metal Stent and Drug-Eluting Stent Trials.
    Alsidawi S; Effat M; Rahman S; Abdallah M; Leesar M
    Cardiovasc Ther; 2015 Dec; 33(6):360-6. PubMed ID: 26363283
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of bioresorbable vs durable polymer drug-eluting stents in unprotected left main (from the RAIN-CARDIOGROUP VII Study).
    Iannaccone M; Barbero U; De Benedictis M; Imori Y; Quadri G; Trabattoni D; Ryan N; Venuti G; Montabone A; Wojakowski W; Rognoni A; Helft G; Parma R; De Luca L; Autelli M; Boccuzzi G; Mattesini A; Templin C; Cerrato E; Wańha W; Smolka G; Huczek Z; Tomassini F; Cortese B; Capodanno D; Chieffo A; Nuñez-Gil I; Gili S; Bassignana A; di Mario C; Doronzo B; Omedè P; D'Amico M; Tedeschi D; Varbella F; Luscher T; Sheiban I; Escaned J; Rinaldi M; D'Ascenzo F
    BMC Cardiovasc Disord; 2020 May; 20(1):225. PubMed ID: 32414330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fracture with the newer bioresorbable vascular scaffolds.
    Elwany M; Di Palma G; Cortese B
    Catheter Cardiovasc Interv; 2017 Oct; 90(4):582-583. PubMed ID: 28295999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.